Trace is a multidisciplinary and multicenter patient-derived tumor xenograft (PDTX) platform, located at the KU Leuven – UZ Leuven Institute in Belgium. The platform aims to be the leading group and reference for PDX models in Belgium and is also a council member and active partner of the EuroPDX Consortium (www.europdx.eu), which allows the platform to be interactive on an international level.
Frédéric Amant, MD, PhD is a specialist in Gynaecological Oncology at the University Hospitals Leuven (UZ Leuven, Gasthuisberg), Belgium, and at Antoni van Leeuwenhoek – Netherlands Cancer Institute (Center for Gynaecological Oncology Amsterdam), the Netherlands. He is professor at the KU Leuven, Belgium, where he heads the scientific section of his speciality. In 2012, he obtained a grant from the National Cancer Plan which allowed him to start the Patient Derived Tumor Xenograft Platform, now Trace, at the KU Leuven, and he also heads the International Network on ‘Cancer, Infertility and Pregnancy (INCIP)’ of the European Society of Gynaecological Oncology (ESGO) (www.cancerinpregnancy.org). In the Hepamut project, Trace will be involved in the development of HCC-PDX models and testing of the efficacy of adoptive T cell therapy and monoclonal antibodies against relevant mutated proteins in HCC in these newly established HCC-PDX models.